Note: FY24 loss includes large one-off impairments and write-offs
Market cap, ratios, CAGR and revenue: company table snapshot as of 30 Oct 2026 (the same figures on every page). Price: snapshot as of 30 Oct 2026. Not investment advice.
Where it fits
Runs multi-step chemical synthesis (or fermentation) from KSMs and intermediates to produce the active drug substance, files Drug Master Files (DMFs) with regulators, and sells it to formulators worldwide - or uses it captively for its own generics.
Why it matters
India is one of the world's two big API hubs and holds the largest number of USFDA DMFs after the US. Backward integration into APIs is what lets Indian formulators survive US price erosion, and Western buyers' China+1 sourcing makes compliant Indian API capacity strategically valuable.
Where the value pool sits
Commodity APIs (paracetamol, metformin, ibuprofen, antibiotics) earn 10-15% EBITDA and swing with Chinese pricing; niche, high-potency, peptide and complex APIs earn 25-40%. Divi's shows the top end: scale, cost leadership and a clean regulatory record turn API chemistry into a 30%+ margin franchise.
Key drivers
China+1 API sourcing by US/EU generic and innovator companies
Captive demand from Indian formulators
GLP-1 / peptide and other new-generation APIs coming off patent
PLI bulk-drug scheme support
Potential bottlenecks
Dependence on Chinese KSMs and intermediates (70%+ of imports for many critical APIs come from China, per PIB data cited for FY24-FY25)
Environmental clearances and effluent treatment for chemistry sites
Solvent and energy cost volatility
Investor metrics to watch
Revenue mix: generic API vs custom/complex
Number of DMFs and regulated-market share of sales
Gross margin vs Chinese spot prices for key molecules